PEPTIDE RESEARCH TOPIC

VIP / Aviptadil Research Peptide

Explore VIP and Aviptadil, vasoactive intestinal peptide signaling, pulmonary clinical studies, physiological roles, and product-specific evidence limitations.

TOPIC OVERVIEW

About VIP / Aviptadil

Identity and names

VIP stands for vasoactive intestinal peptide. Aviptadil is a pharmaceutical name for synthetic VIP; endogenous VIP and finished medicines require separate context.

Compound type

VIP is a signaling peptide with physiological roles across multiple tissues. A clinical formulation is not interchangeable with an unspecified research preparation.

Mechanism

VIP signals through VPAC receptors and has vascular, secretory, and immune-related actions. Effects depend on tissue, route, and exposure.

Research focus and evidence

Clinical studies have examined pulmonary hypertension and respiratory failure, alongside a broader preclinical literature. Outcomes are indication-specific.

Regulatory status and limits

Regulatory status varies by product, combination, indication, and country. A non-U.S. authorization must not be described as FDA approval of VIP generally.

Topics covered
  • VPAC signaling
  • Aviptadil identity
  • pulmonary trials
  • jurisdiction and formulation
Common names and related terms: VIP, Vasoactive intestinal peptide, Aviptadil
RESEARCH SUMMARY

What Is VIP / Aviptadil?

LAST VERIFIEDOctober 7, 2026

A randomized trial investigated intravenous aviptadil in critical COVID-19 respiratory failure. Its primary endpoint was not statistically significant, despite positive secondary or subgroup findings; the trial does not establish benefits for unrelated uses. Aviptadil randomized respiratory-failure trial

An inhalation study examined VIP in pulmonary hypertension. Inhaled and intravenous administration have different exposure contexts and should not be combined into one generalized efficacy claim. VIP inhalation study

RESEARCH TRACKER

VIP / Aviptadil Development & Clinical Research

Current programs, research areas, study status, enrollment, and expected completion dates organized from primary registry records.

LAST VERIFIEDOctober 7, 2026
Registered records13
Active studies1
Completed studies9
Phase 3 studies5
DeveloperRegistry sponsors include QuantumLeap Healthcare Collaborative. Sponsor identity does not establish product approval.
AliasesVIP, Vasoactive intestinal peptide, Aviptadil
Biological targetsVIP signals through VPAC receptors and has vascular, secretory, and immune-related actions. Effects depend on tissue, route, and exposure.
Development stageRegistered intervention phases: Phase 1, Phase 2, Phase 2 / Phase 3, Phase 3. See study-specific context.
Regulatory statusRegulatory status varies by product, combination, indication, and country. A non-U.S. authorization must not be described as FDA approval of VIP generally.

What current projects are studying

Covid19ARDSSARS-CoV 2COVIDALIAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)Dyspnea
SELECTED CURRENT RESEARCH

Latest and important projects

Showing 1 of 1 active studies
I-SPY_COVIDNCT04488081

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

COVID-19

Phase
Phase 2
Status
Active Not Recruiting
Enrollment
1,500 Estimated
Expected completion
Jul 31, 2030
Record updated
Mar 16, 2026
Lead sponsor
QuantumLeap Healthcare Collaborative
Primary sources: ClinicalTrials.gov (defined search)Checked October 7, 2026. Counts include interventional registry records with an explicit matching intervention name or alias; broad search results, biomarker-only observations, and unrelated compounds are excluded. Active includes recruiting, not yet recruiting, active not recruiting, and enrolling by invitation. PubMed is the linked title/abstract query count, not a number of clinical trials or a measure of evidence quality.

Registry status does not establish safety, efficacy, or regulatory approval.

START HERE

Essential VIP / Aviptadil guides

VIP / AVIPTADIL KNOWLEDGE ARTICLESPage 1 of 2
03
KNOWLEDGE ARTICLE

VIPoma Treatment: Options for This Rare Tumor

VIPoma treatment combines fluid and electrolyte replacement with somatostatin analogs, surgery, and liver-directed therapy for this rare neuroendocrine tumor.

↗
05
KNOWLEDGE ARTICLE

How to Make VIP Nasal Spray: Step-by-Step Guide

Learn how to make VIP nasal spray with sterile technique, the right diluent, and accurate concentration math, plus storage, safety, and ingredient tips.

↗
07
KNOWLEDGE ARTICLE

VIP Peptide Benefits: Research, Dosage, and Safety

VIP peptide benefits may include vasodilation, gut support, and immune balance. Here's what research shows on vasoactive intestinal peptide dosing and safety.

↗
10
KNOWLEDGE ARTICLE

VIP Peptide Side Effects: What Research Shows

VIP peptide side effects can include flushing, low blood pressure, headache, and stomach upset. Here's what research shows and when to talk to a doctor.

↗
12
KNOWLEDGE ARTICLE

VIP Peptides: Research Uses, Dosage, and Safety

VIP peptides are research-only compounds studied for gut, immune, and neuro effects. Learn what VIP peptide does, dosage research, and safety facts.

↗
15
KNOWLEDGE ARTICLE

VIP Peptide Reconstitution: Step-by-Step Guide

VIP peptide reconstitution explained: supplies, mixing ratios, storage, and safety notes for researchers handling vasoactive intestinal peptide.

↗
16
KNOWLEDGE ARTICLE

VIP Peptide Dosage: Research Guide & Protocols

Learn how a typical VIP peptide dosage is researched, including subcutaneous protocols, 5 mg and 10 mg vial math, side effects, and safety considerations.

↗
20
KNOWLEDGE ARTICLE

VIP Nasal Spray Side Effects: What to Expect

VIP nasal spray side effects include nasal irritation, headache, flushing, and drops in blood pressure. See what research and user reports say first.

↗